Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

Abstract Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐aflibercept in routine clinical practice was evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Fernández Montes, Nieves Martínez Lago, Marta Covela Rúa, Juan de la Cámara Gómez, Paula González Villaroel, José Carlos Méndez Méndez, Mónica Jorge Fernández, Mercedes Salgado Fernández, Margarita Reboredo López, Guillermo Quintero Aldana, María Luz Pellón Augusto, Begoña Graña Suárez, Jesús García Gómez
Format: Article
Language:English
Published: Wiley 2019-03-01
Series:Cancer Medicine
Subjects:
aflibercept
FOLFIRI
metastatic colorectal cancer
real‐life study
routine clinical practice
VELOUR
Online Access:https://doi.org/10.1002/cam4.1903
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.1903

Similar Items